Alvotech (ALVO) Projected to Post Quarterly Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is projected to announce its earnings results after the market closes on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.74) per share and revenue of $97.99 million for the quarter. Individual that wish to listen to the company’s conference call can do so using this link.

Alvotech Price Performance

Shares of ALVO opened at $11.56 on Tuesday. The company has a market cap of $3.49 billion, a PE ratio of -6.25 and a beta of -0.16. The firm has a 50-day moving average of $12.17 and a 200-day moving average of $12.18. Alvotech has a one year low of $9.15 and a one year high of $14.76.

Wall Street Analysts Forecast Growth

Separately, UBS Group assumed coverage on shares of Alvotech in a report on Friday, February 14th. They set a “buy” rating and a $18.00 target price for the company.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.